Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
! T4 Z7 s$ M+ W1 Y5 ]+ X" c" j/ f0 j* Q: j6 u
# o5 i. r: o- z" w6 GSub-category:
' L1 A; ~3 i, h6 nMolecular Targets # P0 i. Q8 ]& ~9 R: n5 }( L
6 h! b3 Q& u5 ~. @- _! s/ Q, |% v' n3 g2 \, C# W) d
Category:' ~" R# A# N% w: G% R
Tumor Biology
2 F/ c6 [# K5 W# Q+ u2 Q6 F0 e. q* X8 n+ B5 [
) Z* S) W1 G/ N7 b! ~0 h9 F( {! R0 [Meeting:. r8 B! B, E( F4 ]6 S- `
2011 ASCO Annual Meeting 5 s ]( s0 ~ m3 R# O
& p+ K4 r4 s @! U$ s
) O" X3 y3 n PSession Type and Session Title:2 k- [$ N9 \) {
Poster Discussion Session, Tumor Biology $ Y' [! f9 E6 _ `2 m
9 ?5 K, D3 U g4 T8 ]) g
& ] e% f3 m7 {" M) }Abstract No:5 Y. k: S- w1 o* m; z
10517
# e" R @+ ^( ~
+ j; |2 p `4 e+ ?) I1 o5 X, T3 z( @ t$ q- x
Citation:
" Z4 p/ w6 ^5 R+ K) h$ WJ Clin Oncol 29: 2011 (suppl; abstr 10517) . J' o4 n5 o; j) U
" n" F0 z( A" Q3 v3 D
( N4 f( h0 ~1 P: ZAuthor(s):7 S' ~0 a9 |' v+ i" Y% h
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China - p$ j9 S5 Q' O3 |! Y" M$ J7 f: U( e
5 ~& m/ S& b" r# d7 ^# j E
$ F# C) q# L/ v
$ r A; S" I# g( n
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.! l! }* N8 t# x8 L7 ~* h
9 U$ N- i8 q0 n ?# N6 d+ k& }
Abstract Disclosures" X1 T. S. F u) K- l
* o1 X; g D( c- P; YAbstract:$ ~4 ~4 v" ?5 ?/ s
( U7 D. x: F# M7 b7 I/ L
0 u5 V6 E* z% R( S& u! K
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.4 p8 _- j7 B8 O& ?5 f( `
. N9 i2 Z7 y8 u+ l# }4 {: s% t6 K
( F' K7 }5 C5 D- I: d |